Long
VBI vaccines $4 EOY Target
Successful completion of the pivotal Phase 3 program for Sci-B-Vac®, on-track for submission of regulatory approval applications in the U.S., Europe, and Canada expected to begin in Q4 2020
Announcement of pan-coronavirus vaccine candidate targeting COVID-19, SARS, and MERS – human clinical study material expected to be available in Q4 2020
Expanded immunologic, tumor, and clinical data from recurrent GBM Phase 2a clinical study of VBI-1901 expected mid-year and Q4 2020
Human proof-of-concept data from Phase 1b/2a study of hepatitis B immunotherapeutic, VBI-2601, expected H2 2020
Net cash proceeds of approximately $54 million added to balance sheet from underwritten public offering in April 2020
11 Million shares bought by insider https://www.sec.gov/Archives/edgar/data/764195/000119312520122131/d900394dsc13da.htm
Announcement of pan-coronavirus vaccine candidate targeting COVID-19, SARS, and MERS – human clinical study material expected to be available in Q4 2020
Expanded immunologic, tumor, and clinical data from recurrent GBM Phase 2a clinical study of VBI-1901 expected mid-year and Q4 2020
Human proof-of-concept data from Phase 1b/2a study of hepatitis B immunotherapeutic, VBI-2601, expected H2 2020
Net cash proceeds of approximately $54 million added to balance sheet from underwritten public offering in April 2020
11 Million shares bought by insider https://www.sec.gov/Archives/edgar/data/764195/000119312520122131/d900394dsc13da.htm
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.